Aprea Therapeutics Inc. (APRE)
2.20
-0.06 (-2.65%)
At close: Mar 25, 2025, 3:59 PM
2.27
2.96%
Pre-market: Mar 26, 2025, 07:02 AM EDT
-2.65% (1D)
| Bid | 2.25 |
| Market Cap | 11.96M |
| Revenue (ttm) | 874.94K |
| Net Income (ttm) | -12.36M |
| EPS (ttm) | -2.8 |
| PE Ratio (ttm) | -0.79 |
| Forward PE | -4.09 |
| Analyst | Buy |
| Ask | 2.35 |
| Volume | 15,167 |
| Avg. Volume (20D) | 29,979 |
| Open | 2.26 |
| Previous Close | 2.26 |
| Day's Range | 2.17 - 2.26 |
| 52-Week Range | 2.15 - 6.80 |
| Beta | 1.57 |
About APRE
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATR...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 3, 2019
Employees 7
Stock Exchange NASDAQ
Ticker Symbol APRE
Website https://atrinpharma.com
Analyst Forecast
According to 2 analyst ratings, the average rating for APRE stock is "Buy." The 12-month stock price forecast is $15.5, which is an increase of 604.55% from the latest price.
Stock ForecastsEarnings Surprise
Aprea Therapeutics has released their quartely earnings
on Mar 25, 2025:
2 weeks ago
+9.87%
Aprea Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
